Genentech’s Evrysdi (risdiplam) Receives the US FDA’s Priority Review of sNDA for the Treatment of Spinal Muscular Atrophy
Shots:
- The sNDA submission is based on the (RAINBOWFISH) study evaluating the efficacy, safety, PK & PD of Evrysdi in 25 patients aged birth to 6wks. with SMA
- In an interim efficacy analysis, babies treated with Evrysdi maintained the ability to swallow & were able to feed orally while 80% (4/5) were able to sit, stand and walk independently & all participants met HINE-2 motor milestones of head control, sitting upright, rolling and crawling after 12mos. of treatment
- Additionally, no treatment-related serious AEs were reported & the latest results from the will be presented at MDA in Mar 2022. The therapy has received PRIME designation from the EMA in 2018 & ODD from the US FDA in 2017
Ref: Businesswire | Image: Slide Genius
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
